Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: A wham, bam but no alakazama in a seesaw session with volatility dragged down by dispersion selling

May 17, 2021 5:24pm

Repositions going-on post most earnings reported (30 of my 35 covered)

Pre-open indication performance: 1 MISS

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the slide of share pricing! My comments are important in trying to distinguish the temporary from real pricing digression or progress.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!

We crave certainty, there is more of it here as indications highlight the possible!

The Dow closed DOWN -54.34 points (-0.16%); the S&P closed DOWN -10.56 points (-0.25%) while the Nasdaq closed DOWN -50.93 points (-0.38%)

Henry’omics:

Weakness led the major indexes lower on Monday after last week’s hotter-than-expected inflation readings sparked a downturn in equity markets.

An appropriate quote, ““Investors should brace for further bouts of volatility, driven by inflation data along with other risks, such as setbacks in curbing the pandemic,” said Mark Haefele, UBS’ chief investment officer. “But we don’t see inflation concerns ending the rally in stocks, which we expect to be led by cyclical parts of the market as the global economic reopening broadens.” <CNBC>

RegMed Investors’ (RMi) pre-open: “wham bam, no alakazam. Who will buy the latest rotation now?” … https://www.regmedinvestors.com/articles/11913

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

Monday opened negative at 6/26, 2 flat and 1 acquired, flipped positive at the mid-day to 62111, 2 flats and 1 acquired, closing negative at 14/18, 2 flats and 1 acquired;

Pre-open indication results: 1 MISS < Biostage (BSTG -$0.00 at $1.15 with 1542 shares traded “pumped and promoted” volume and pricing),

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … to date: https://www.regmedinvestors.com/articles/11628

Bellicum Pharmaceuticals (BLCM) reported and dropped -$0.15 or -4.78% to $2.99,
Applied Genetic Technologies (AGTC) reported and dropped -$0.04 or -1.03% to $3.84.

There are clear winners and losers

Jumping with share pricing momentum:

CRISPR Therapeutics (CRSP), Sage therapeutics (SAGE), Chinook Therapeutics (KDNY), BioLife Solutions (BLFS), Ultragenyx (RARE) to name 5 of the 14 inclining of the 35 covered

Hammered in today’s market:

Regenxbio (RGNX), Ionis Pharmaceuticals (IONS), uniQure NV (QURE), Fate Therapeutics (FATE), AxoGen (AXGN) to name 5 of the 18 declining of the 35 covered

Key metrics:

Sector volume was LOW with 2 of the 14-upside having higher than the 3-month average volume with the volume of 1 of 18-downside having higher than the 3-month average volume;

Monday’s percentage (%) of the 14-upside were +0.14% (ALNY) to +13.04% (BSTG) while the 18-downside ranges from -0.31% (FIXX) to -4.78% (BLCM);

Monday’s (10 of 14) incliners:

CRISPR Therapeutics (CRSP +$2.58);
Sage Therapeutics (SAGE +$1.89);
Chinook Therapeutics (KDNY +$1.87);
BioLife Solutions (BLFS +$0.82);
Vericel (VCEL +$0.25);
Mesoblast MESO +$0.23);
Alnylam Pharmaceuticals (ALNY +$0.19);
Pluristem (PSTI +$0.17);
Biostage (BSTG +$0.15 – “pumped”);
Global Blood therapeutics (GBT +$0.13);

Monday’s (10 of 18) decliners:

Regenxbio (RGNX -$1.40);
Ionis Pharmaceuticals (IONS -$0.92);
uniQure NV (QURE -$0.73);
Ultragenyx (RARE -$0.59);
bluebird bio (BLUE -$0.41);
AxoGen (AXGN -$0.39);
Fate Therapeutics (FATE -$0.36);
Intellia Therapeutics (NTLA -$0.35);
MiMedx (MDXG -$0.27);
Precigen (PGEN -$0.21);

Closing 2 – Verastem (VSTM), ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML – acquired)

COVID-19 updates:

U.S. Covid case counts continued to decline, with data compiled by Johns Hopkins University showing the nationwide average at about 33,200 new cases per day, the lowest level since late June.
The U.S. is reporting an average of 1.9 million vaccinations per day over the past week, according to CDC data, and 47.4% of the population has received at least one vaccine dose. <CNBC>

Monday’s COVID Data Tracker <Million>:

Cases: 32.75 M
Death rate totaled 582,769 - dipping <Johns Hopkins University>
Vaccinations: 59.7% <adding 1%>

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday, the IBB closed up +0.21% and XBI closed down -0.23%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Monday was up +0.91 points or +4.84% at 19.72

Upside volume: low

Monday: 2 out of the 14-upside had higher than the 3-month average volume;

Downside volume: low

Monday: 1 out of the 18-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: LOW % with limited pricing drops as upside maintains

Monday’s percentage (%) of the 14-upside were +0.14% (ALNY) to +13.04% (BSTG) while the 18-downside ranges from -0.31% (FIXX) to -4.78% (BLCM);

May, second month of Q2/21:

Monday (5/17) closed negative with 14 advancers, 18 decliners, 2 flat and 1 acquired

The BOTTOM LINE: Q1 earnings season is wrapping up and my reaction to earnings LPS (loss-per-share) results reveals more than some skepticism that Q1 losses provide a reason for additional forward-looking less than optimistic and more pessimism through the mid-year.”

Reiterating, the cell and gene therapy sector has been experiencing “whiplash which is more than an event or an accident”.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

My time frame of measurement is Friday to Friday and been proved right again, don’t get complacent …

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.